Ebsteins anomaly of the tricuspid valve risk factors

Ebsteins anomaly of the tricuspid valve Microchapters
Home
Patient Information
Overview
Historical Perpective
Classification
Pathophysiology
Causes
Differentiating Ebstein's Anomaly from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
Echocardiography
CT
MRI
Other Imaging Findings
Other diagnostic studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Case Studies
Case #1
Ebsteins anomaly of the tricuspid valve risk factors On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Ebsteins anomaly of the tricuspid valve risk factors All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Ebsteins anomaly of the tricuspid valve risk factors
CDC on Ebsteins anomaly of the tricuspid valve risk factors
Ebsteins anomaly of the tricuspid valve risk factors in the news
Blogs on Ebsteins anomaly of the tricuspid valve risk factors
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Ebsteins anomaly of the tricuspid valve risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Claudia P. Hochberg, M.D.

Overview

The development of Ebstein's anomaly is associated with the administration of Lithium Carbonate during the first trimester or benzodiazepines during pregnancy. Maternal exposure to varnishing substances is also a risk factor as is a previous history of fetal loss in the mother.